CAR-T cell therapy for active lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new treatment called ATHENA CAR-T for people with active systemic lupus erythematosus (SLE). The treatment uses your own immune cells, modified to target and calm the overactive immune system that causes lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 56 years old.
- You must have a confirmed diagnosis of systemic lupus erythematosus (SLE).
- Your lupus must be active despite at least 6 months of standard treatment (like steroids or immunosuppressants).
- You cannot have had prior CAR-T therapy, other gene therapy, or CD19-targeted treatment.
- You must not have serious kidney disease from lupus, active cancer, or uncontrolled infections.
- If you are of childbearing potential, you must agree to use effective contraception for 24 months after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cell therapy for people with severe lupus that hasn't improved with usual treatments. The therapy uses your own immune cells to target and reduce the abnormal immune response that causes lupus symptoms.
This study tests a new type of treatment called CAR-T cells, which are specially engineered immune cells that may help control lupus by targeting the cells causing the disease. If you have active lupus despite standard treatments, this therapy might offer a new option to reduce symptoms and improve your condition.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.